Agatolimod

Singapore, 22nd October 2025 – ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM’s proprietary polymersome platform through a strategic collaboration with the National Cancer Centre Singapore (NCCS). Preclinical experiments show that the ACM nanoparticle formulation fundamentally alters CpG’s mechanism of action, enabling myeloid modulation through comprehensive TLR9 engagement in immunologically “cold” tumors. The ongoing Phase 1 trial (NCT06587295)i is enrolling patients with advanced solid tumors at NCCS to assess the safety, tolerability, and pharmacodynamic effects of ACM-CpG. Early clinical data indicate that these preclinical findings are translating into humans. In patients with advanced solid tumors, intramuscular administration of ACM-CpG – at weekly or biweekly doses as low as 0.25mg CpG – has demonstrated robust systemic immune activation as evidenced through immune biomarker data. The therapy shows a highly favorable safety and tolerability profile and to date, no dose-limiting toxicities have been observed. “TLR9 has long been recognized as a validated immunologic target, but its therapeutic potential has been limited by delivery and safety limitations,” said Dr. Madhavan Nallani, CEO of ACM Biolabs. “Our intramuscular nanoparticle delivery enables systemic immune activation with an excellent safety profile, creating opportunities not only for combination approaches but also for targeted monotherapy in patient populations with few treatment options. Over time, this platform can also support additional routes of administration allowing us to tailor treatment strategies to diverse tumor settings and address significant unmet medical needs.” “TLR9 has long been recognized as a validated immunologic target, but its therapeutic potential has been limited by delivery and safety limitations,” said Dr. Madhavan Nallani, CEO of ACM Biolabs. “Our intramuscular nanoparticle delivery enables systemic immune activation with an excellent safety profile, creating opportunities not only for combination approaches but also for targeted monotherapy in patient populations with few treatment options. Over time, this platform can also support additional routes of administration allowing us to tailor treatment strategies to diverse tumor settings and address significant unmet medical needs.” “The safety profile and clear pharmacodynamic activity we have observed so far are very encouraging, with two out of the three patients enrolled at the 0.25mg dose level having ongoing disease control for eight months with monotherapy alone.” said Dr. Amit Jain, Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. “We look forward to exploring ways to optimize its delivery and maximize its therapeutic potential for patients with advanced cancers.” “The safety profile and clear pharmacodynamic activity we have observed so far are very encouraging, with two out of the three patients enrolled at the 0.25mg dose level having ongoing disease control for eight months with monotherapy alone.” said Dr. Amit Jain, Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. “We look forward to exploring ways to optimize its delivery and maximize its therapeutic potential for patients with advanced cancers.” The collaboration is supported in part by funding from Singapore’s Industry Alignment Fund – Pre-Positioning (IAF-PP), which fosters strategic collaborations between industry and research institutes. This study is evaluating ACM-CpG in patients with advanced head and neck, lung, bladder, and kidney cancers and is designed to establish proof of mechanism to support global clinical development. About ACM Biolabs Pte Ltd ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company’s pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. Media contacts Dr Peter Moran Email: peter.moran@acmbiolabs.com General Inquiries: BD@acmbiolabs.com About ACM Biolabs Pte Ltd ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company’s pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. Media contacts Dr Peter Moran Email: peter.moran@acmbiolabs.com General Inquiries: BD@acmbiolabs.com ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company’s pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. Media contacts Dr Peter Moran Email: peter.moran@acmbiolabs.com General Inquiries: BD@acmbiolabs.com 1 https://www.clinicaltrials.gov/study/NCT06587295

April – June 2025 Net sales amounted to 0 (0) KSEK The operating result for the period was -836 (-2 391) KSEK The net result was -733 (-2 398) KSEK corresponding to earnings per share of -0,01 (-0.02) SEK Cash flow from operating activities amounted to -1 594 (-2 938) KSEK Cash and cash equivalents amounted to 2 350 (8 009) KSEK January – June 2025 Net sales amounted to 0 (0) KSEK The operating result for the period was -2 091 (-2 392) KSEK The net result was -2 044 (-2 404) KSEK corresponding to earnings per share of -0,01 (-0.02) SEK Cash flow from operating activities amounted to -2 333 (-3 002) KSEK Significant events January – June 2025 On April 2, the board of directors decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202. Taking into account the principle of prudence, the board of directors, decided on April 10 to write down the book values of all intangible assets in LIDDS and Noviga as of 2024-12-31. This decision resulted in a deviation for the annual report compared to the published year-end report for 2024. Due to the reasons to believe that the company’s equity was less than on-half of the registered share capital, the board of directors decided to prepare a balance sheet for liquidation purpose on April 22. The balance sheet for liquidation purpose prepared and reviewed by the company’s auditor showed that the equity was less than half of the registered share capital and therefore the board of directors decided on April 24 to call a first control meeting. At the annual general meeting, at the same time first control meeting, on May 28, it was decided that the company will continue its operations and not be liquidated. CEO Statement During the second quarter, the company has continued to focus on the commercialisation of the three projects Nanoimod, Nanodotax and NOV 202, as well as exploring interest in the company’s listing on First North. So far, these efforts have not yet resulted in any concrete successes. The quarter has also been characterised by extensive work on finalising the annual report, holding the annual general meeting, and managing the situation where the company’s equity was found to be less than half of the share capital. Following the decision at the first control meeting to continue operations and not initiate liquidation, the company now has eight months before the question of potential liquidation needs to be reconsidered. Mats WikingCEO and CFO The interim report is available on the company’s website https://liddspharma.com/en/investors/financial-reports/ For additional information, please contact Mats Wiking, CEO and CFOPhone: +46 (0)70 620 04 00E-mail: mats.wiking@liddspharma.com Daniel Lifveredson, Chairman of the BoardTelefon: +46 (0) 70-916 21 01Email: d.li@excore.com LIDDS’ Certified Adviser is Redeye AB LIDDS in brief: LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market. Attachments LIDDS Interim Report Q2 2025